178 J ournal of Medicinal Chemistry, 2001, Vol. 44, No. 2
Harada et al.
(2) (a) Libert, F.; Schiffmann, S. N.; Lefort, A.; Parmentier, M.;
Gerard, C.; Dumont, J . E.; Vanderhaeghen, J . J .; Vassart, G.
The Orphan Receptor cDNA RDC7 Encodes an A1 Adenosine
Receptor. EMBO J . 1991, 10, 1677-1682. (b) Libert, F.; van
Sande, J .; Lefort, A.; Czernilofsky, A.; Dumont, J . E.; Vassart,
G.; Ensinger, H. A.; Mendla, K. D. Cloning and Functional
Characterization of a Human A1 Adenosine Receptor. Biochem.
Biophys. Res. Commun. 1992, 187, 919-926.
(3) (a) Maenhaut, C.; Sande, J . V.; Libert, F.; Abramowicz, M.;
Parmentier, M.; Vanderhaeghen, J . J .; Dumont, J . E.; Vassart,
G.; Schiffmann, S. RDC8 Codes for an Adenosine A2 Receptor
with Physiological Constitutive Activity. Biochem. Biophys. Res.
Commun. 1990, 173, 1169-1178. (b) Furlong, T. J .; Pierce, K.
D.; Selbie, L. A.; Shine, J . Molecular Characterization of a
Human Adenosine A2 Receptor. Mol. Brain Res. 1992, 15, 62-
66.
(4) (a) Stehle, J . H.; Rivkees, S. A.; Lee, J . J .; Weaver, D. R.; Deeds,
J . D.; Reppert, S. M. Molecular Cloning and Expression of the
cDNA for a Novel A2-Adenosine Receptor Subtype. Mol. Endo-
crinol. 1992, 6, 384-393. (b) Pierce, K. D.; Furlong, T. J .; Selbie,
L. A.; Shine, J . Molecular Cloning and Expression of an Ad-
enosine A2B Receptor from Human Brain. Biochem. Biophys. Res.
Commun. 1992, 187, 86-93.
(5) (a) Zhou, Q. Y.; Li, C. Y.; Olah, M. E.; J ohnson, R. A.; Stiles, G.
L.; Civelli, O. Molecular Cloning and Characterization of an
Adenosine Receptorsthe A3 Adenosine Receptor. Proc. Natl.
Acad. Sci. U.S.A. 1992, 89, 7432-7436. (b) Salvatore, C. A.;
J acobson, M. A.; Tailor, H. E.; Linden, J .; J ohnson, R. G.
Molecular Cloning and Characterization of the Human A3
Adenosine Receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90,
10365-10369.
(6) (a) DeFronzo, R. A.; Bonasonna, R. C.; Ferrannini, E. Patho-
genesis of NIDDM: A Balanced Overview. Diabetes Care 1992,
15, 318-368. (b) Wolffenbuttel, B. H. R.; van Haeften, T. W.
Prevention of Complications in Non-Insulin-Dependent Diabetes
Mellitus (NIDDM). Drugs 1995, 50, 263-288.
(7) Buxton, D. B.; Fisher, R. A.; Robertson, S. M.; Olson, M. S.
Stimulation of Glycogenolysis and Vasoconstriction by Adenosine
and Adenosine Analogues in the Perfused Liver. Biochem. J .
1987, 248, 35-41.
(8) McLane, M. P.; Black, P. R.; Law, W. R.; Raymond, R. M.
Adenosine Reversal of In Vivo Hepatic Responsiveness to
Insulin. Diabetes 1990, 39, 62-69.
(9) (a) Challiss, R. A. J .; Budohoski, L.; McManus, B.; Newsholme,
E. A. Effects of an Adenosine-Receptor Antagonist on Insulin-
Resistance in Soleus Muscle from Obese Zucker Rats. Biochem.
J . 1984, 221, 915-917. (b) Challiss, R. A. J .; Richards, S. J .;
Budohoski, L. Characterization of the Adenosine Receptor
Modulating Insulin Action in Rat Skeletal Muscle. Eur. J .
Pharmacol. 1992, 226, 121-128.
(10) (a) Xu, B.; Berkich, D. A.; Crist, G. H.; LaNoue, K. F. A1
Adenosine Receptor Antagonism Improves Glucose Tolerance in
Zucker Rats. Am. J . Physiol. 1998, 274, E271-E279. (b) Crist,
G. H.; LaNoue, K. F.; Lang, C. H. Tissue-Specific Effects of in
vivo Adenosine Receptor Blockage on Glucose Uptake in Zucker
Rats. FASEB J . 1998, 12, 1301-1308.
(11) Gerich, J . E. Is Muscle the Major Site of Insulin Resistance in
Type 2 (Non-Insulin-Dependent) Diabetes Mellitus? Diabetologia
1991, 34, 607-610.
(12) Mu¨ller, C. E.; Stein, B. Adenosine Receptor Antagonists: Struc-
ture and Potential Therapeutic Applications. Curr. Pharm. Des.
1996, 2, 501-530.
(13) J acobson, K. A.; Ijzerman, A. P.; Linden, J . Novel 1,3-Dialky-
lxanthine Derivatives Having High Potency as Antagonists at
Human A2B Adenosine Receptors. Drug. Dev. Res. 1999, 47, 45-
53.
(14) Prasad, R. N.; Bariana, D. S.; Fung, A.; Savic, M.; Tietje, K.;
Stein, H. H.; Brondyk, H.; Egan, R. S. Modification of the 5′
Position of Purine Nucleosides. 2. Synthesis and Some Cardio-
vascular Properties of Adenosine-5′-(N-substituted)carbox-
amides. J . Med. Chem. 1980, 23, 313-319.
(15) de Zwart, M.; Link, R.; von Frijtag Drabbe Ku¨nzul, J . K.;
Cristalli, G.; J acobson, K. A.; Townsend-Nicholson, A.; Ijzerman,
A. P. A Functional Screening of Adenosine Analogues at the
Adenosine A2B Receptor: A Search for Potent Agonists. Nucleo-
sides Nucleotides 1998, 17, 969-985.
Receptor Agonists with Potent Antihypertensive Effects. J . Med.
Chem. 1992, 35, 241-252. (c) Abiru, T.; Miyashita, T.; Watanabe,
Y.; Yamaguchi, T.; Machida, H.; Matsuda, A. Nucleosides and
Nucleotides. 107. 2-(Cycloalkylalkynyl)adenosines: Adenosine
A2 Receptor Agonists with Potent Antihypertensive Effects. J .
Med. Chem. 1992, 35, 2253-2260. (d) Homma, H.; Watanabe,
Y.; Abiru, T.; Murayama, T.; Momura, Y.; Matsuda, A. Nucleo-
sides and Nucleotides. 112. 2-(1-Hexyn-1-yl)Adenosine-5′-uron-
amides: A New Entry of Selective A2 Adenosine Receptor
Agonists with Potent Antihypertensive Activity. J . Med. Chem.
1992, 35, 2881-2890. (e) Cristalli, G.; Eleuteri, A.; Vittori, S.;
Volpini, R.; Lohse, M. J .; Klotz, K.-N. 2-Alkynyl Derivatives of
Adenosine and Adenosine-5′-N-ethyluronamide as Selective Ago-
nists at A2 Adenosine Receptors. J . Med. Chem. 1992, 35, 2363-
2368. (f) Cristalli, G.; Volpini, R.; Vittori, S.; Camaioni, E.;
Monopoli, A.; Conti, A.; Dionisotti, S.; Zocchi, C.; Ongini, E.
2-Alkynyl Derivatives of Adenosine-5′-N-ethyluronamide: Selec-
tive A2 Receptor Agonists with Potent Inhibitory Activity on
Platelet Aggregation. J . Med. Chem. 1994, 37, 1720-1726. (g)
Cristalli, G.; Camaioni, E.; Vittori, S.; Volpini, R.; Borea, P. A.;
Conti, A.; Dionisotti, S.; Ongini, E.; Monopoli, A. 2-Aralkynyl
and 2-Heteroalkynyl Derivatives of Adenosine-5′-N-ethylurona-
mide as Selective A2A Adenosine Receptor Agonists. J . Med.
Chem. 1995, 38, 1462-1472.
(18) (a) Hutchison, A. J .; Williams, M.; Dejesus, R.; Yokoyama, R.;
Oei, H. H.; Ghai, G. R.; Webb, R. L.; Zoganas, H. C.; Stone, G.
A.; J arvis, M. F. 2-(Arylalkylamino)adenosin-5′-uronamides: A
New Class of Highly Selective Adenosine A2 Receptor Ligands.
J . Med. Chem. 1990, 33, 1919-1924. (b) Francis, J . E.; Webb,
R. L.; Ghai, G. R.; Hutchison, A. J .; Moskal, M. A.; deJ esus, R.;
Yokoyama, R.; Rovinski, S. L.; Contardo, N.; Dotson, R.; Barclay,
B.; Stone, G. A.; J arvis, M. F. Highly Selective Adenosine A2
Receptor Agonists in a Series of N-Alkylated 2-Aminoadenosines.
J . Med. Chem. 1991, 34, 2570-2579.
(19) (a) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A.
2-Alkoxyadenosines: Potent and Selective Agonists at the
Coronary Artery A2 Adenosine Receptor. J . Med. Chem. 1991,
34, 1334-1339. (b) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.;
Olsson, R. A. 2-Aralkoxyadenosines: Potent and Selective Ago-
nists at the Coronary Artery A2 Adenosine Receptor. J . Med.
Chem. 1991, 34, 1340-1944.
(20) Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N.;
Cristalli, G. New Substituted 9-Alkylpurines as Adenosine
Receptor Ligands. Bioorg. Med. Chem. 1998, 6, 523-533.
(21) Asano, O.; Harada, H.; Hoshino, Y.; Yoshikawa, S.; Inoue, T.;
Horizoe, T.; Yasuda, N.; Nagata, K.; Nagaoka, J .; Murakami,
M.; Kobayashi, S. Purine Derivatives and Adenosine A2 Receptor
Antagonists Serving as Preventives/Remedies for Diabetes. PCT
Patent WO9935147, 1999.
(22) Alexander, S. P. H.; Cooper, J .; Shine, J .; Hill, S. Characteriza-
tion of the Human Brain Putative A2B Adenosine Receptor
Expressed in Chinese Hamster Ovary (CHO.A2B4) Cells. Br. J .
Pharmacol. 1996, 119, 1286-1290.
(23) Akahane, A.; Katayama, H.; Mitsunaga, T.; Kita, Y.; Kusunoki,
T.; Terai, T.; Yoshida, K.; Shinokawa, Y. Discovery of FK453, A
Novel Non-Xanthine Adenosine A1 Receptor Antagonist. Bioorg.
Med. Chem. Lett. 1996, 7, 2059-2062.
(24) (a) Shimada, J .; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S.
(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: Po-
tent and Selective Adenosine A2 Antagonists. J . Med. Chem.
1992, 35, 2342-2345. (b) Nonaka, Y.; Shimada, J .; Nonaka, H.;
Koike, N.; Aoki, N.; Kobayashi, H.; Kase, H.; Yamaguchi, K.;
Suzuki, F. Photoisomerization of a Potent and Selective Adeno-
sine A2 Antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-
methylxanthine. J . Med. Chem. 1993, 36, 3731-3733. (c) Suzuki,
F.; Shimada, J .; Ishii, A.; Nonaka, H.; Kosaka, N.; Ichikawa, S.
Xanthine Derivatives. PCT Patent WO, 92/06976, 1992.
(25) (a) J acobson, M. A.; Chakravarty, P. K.; J ohnson, R. G.; Norton,
R. Novel Selective Non-Xanthine A3 Adenosine Receptor An-
tagonists. Drug. Dev. Res. 1996, 37, 131. (b) J acobson, M. A.;
Norton, R.; Chakravarty, P. K. Method for Inhibiting Activation
of the Human A3 Adenosine Receptor to Treat Asthma. US
Patent 5,780,481, 1998.
(26) Nishimura, M. Breeding of Mice Strains for Diabetes Mellitus.
Exp. Anim. 1969, 18, 147-157.
(27) Temple, C., J r.; Smith, B. H.; Montgomery, J . A. Preparation of
2,5-Diamino-4,6-dichloropyrimidine. J . Org. Chem. 1975, 40,
3141-3142.
(28) Robins, R. K.; Lin, H. H. Potential Purine Antagonists. IV.
Synthesis of Some 9-Methyl-6-substituted-purines. J . Am. Chem.
Soc. 1957, 79, 490-494.
(29) Mu¨ller, C. E.; Shi, D.; Manning, M., J r.; Daly, J . W. Synthesis
of Paraxanthine Analogues (1,7-Disubstituted Xanthines) and
Other Xanthines Unsubstituted at the 3-Position: Structure-
Activity Relationships at Adenosine Receptors. J . Med. Chem.
1993, 36, 3341-3349.
(16) Thompson, R. D.; Secunda, S.; Daly, J . W.; Olsson. R. A. N6,9-
Disubstituted Adenines: Potent, Selective Antagonists at the
A1 Adenosine Receptor. J . Med. Chem. 1991, 34, 2877-2882.
(17) (a) Abiru, T.; Yamaguchi, T.; Watanabe, Y.; Kogi, K.; Aihara,
K.; Matsuda, A. The Antihypertensive Effect of 2-Alkynylad-
enosines and Their Selective Affinity for Adenosine A2 Receptors.
Eur. J . Pharmacol. 1991, 196, 69-76. (b) Matsuda, A.; Shi-
nozaki, M.; Yamaguchi, T.; Homma, H.; Nomoto, R.; Miyasaka,
T.; Watanabe, Y.; Abiru, T. Nucleosides and Nucleotides. 103.
2-Alkynyladenosines: A Novel Class of Selective Adenosine A2